What are the open and close dates of the Symbiotec Pharmalab IPO ?

Symbiotec Pharmalab IPO will be open between 2026-08-24 and 2026-08-27.

What is the allotment date for the Symbiotec Pharmalab IPO ?

Symbiotec Pharmalab IPO allotment date is 2026-08-31. For Symbiotec Pharmalab IPO allotment status check, you can visit the website of the registrar of the IPO.

Who is the registrar of Symbiotec Pharmalab IPO ?

For Symbiotec Pharmalab IPO, the IPO registrar is MUFG Intime India Private Limited. You can check Symbiotec Pharmalab IPO allotment status on the website of the registrar.

Where is the Symbiotec Pharmalab IPO getting listed?

The shares are proposed to be listed on the BSE and NSE.

When will Symbiotec Pharmalab IPO shares be credited to your demat account?

The Symbiotec Pharmalab IPO shares will typically be credited to your demat account one working day before the IPO's listing date, provided your application is successfully allotted.

What is the lot size and minimum order quantity of the Symbiotec Pharmalab IPO ?

The Symbiotec Pharmalab IPO lot size is 15 and minimum order quantity is 15.

What is the price band for the Symbiotec Pharmalab IPO ?

Symbiotec Pharmalab IPO has set the price band for its IPO at 988 per equity share with a face value of 2.

Home
/
IPO

82.94x

subscribed

Symbiotec Pharmalab IPO

Pharmaceuticals & Drugs

listed

₹14,070Min. investment

Pre-apply
21 Aug
Bid start
24 Aug
Bid end
27 Aug
Allotment
28 Aug
Release of funds
31 Aug
Demat transfer
31 Aug
Listing
1 Sep

Symbiotec Pharmalab Limited IPO Details

Issue size

₹1,757Cr

IPO type

Mainboard

Market Cap

₹6,244CrLower than sector avg

Price range

₹938 – ₹988

Listing ExchangeBSE, NSE

RevenueApr 2025 - Mar 2026

₹869.1CrLower than sector avg

Lot size

15 shares

Red Herring Prospectus

Read

Growth rate3Y CAGR

10.16%

SectorPharmaceuticals & Drugs

Price range₹938 – ₹988

IPO type

Regular

Lot size15 shares

Issue size₹1,757Cr

Red Herring Prospectus

Read

Market Cap

₹6,244CrLower than sector avg

RevenueApr 2025 - Mar 2026

₹869.1CrLower than sector avg

Growth rate3Y CAGR

10.16%

Symbiotec Pharmalab Limited IPO Overview

Symbiotec Pharmalab Limited IPO Open Date

Symbiotec Pharmalab IPO will open for subscription on August 24, 2026, and the closing date for the IPO is August 27, 2026. After this, investors are expected to be updated about the allotment status on August 28, 2026.

Investors who have been allotted shares can expect them to be credited to their demat account on August 31, 2026. The shares will be listed on the NSE and the BSE on Tuesday, September 01, 2026.

Symbiotec Pharmalab Limited IPO price band

The IPO is a combination of fresh Issue and offer for sale. The IPO price band has been set between ₹938 to ₹988 per share. Interested investors can choose a price within this band to apply for the IPO.

The IPO is a book-building issue, comprising a fresh issue of ₹150 crore and an offer for sale of ₹1,607 crore. Symbiotec Pharmalab IPO listing price will be determined on September 01, 2026. The listing price is the price at which a company’s shares debut on the stock exchanges.

Symbiotec Pharmalab IPO lot size

Symbiotec Pharmalab IPO details have been declared. The minimum lot size for an application is 15 shares, and the investor would have to apply for a minimum of 1 lot. Meanwhile, the IPO issue size is approximately ₹1,757.00 crore.

Checklist

Quality analysis

Revenue growth

Company valuation

Earnings expansion

Risk analysis

Debt to Equity ratio

Promoter holdings

Shares pledged

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Compare

Companies in this sector

Sun Pharmaceutical Industries Ltd

Divi's Laboratories Ltd

Torrent Pharmaceuticals Ltd

Revenue

Higher revenue means strong sales and good market demand

This IPO

₹869.1Cr

This sector

₹1,331.47Cr

Compare with companies

PAT

Higher PAT means strong profitability and efficient cost management

This IPO

₹109.9Cr

This sector

₹193.4Cr

Compare with companies

Market cap

Higher market cap means strong confidence but may suggest overvaluation

This IPO

₹6,244Cr

This sector

₹10,914.84Cr

Compare with companies

P/E ratio

Lower ratio usually means stock is undervalued

This IPO

51.73

This sector

60.87

Compare with companies

D/E ratio

Lower ratio usually means fewer liabilities

This IPO

0.33

This sector

0.43

Compare with companies

Objectives

Repayment of borrowings

75.00%

General corporate purposes

25.00%

Strength and Weakness

Global leadership in some APIs

The company holds global leadership positions in molecules such as Hydrocortisone, Testosterone and Methylprednisolone, with market shares of 80.1%, 76.4% and 76.0%, respectively, in FY26, representing over 50% market share of supply by volume in each of these molecules.

Long-lasting customer relationship

69.49% of revenue from operations at ₹604.01 crore in FY26 contributed by the customers having more than 7 years of relationship with the company. The company added 101 new distinct customers in FY26, 96 in FY25 and 89 in FY24.

Multi scaled, vertically integrated manufacturing platform

As of March 31, 2026, Symbiotec operated two industrial-scale API manufacturing facilities and had commissioned two additional manufacturing facilities, taking aggregate maximum chemical synthesis capacity to 584.67 MT, fermentation capacity to 700 KL and complex injectables capacity to 20 million vials. The company is among the few players in India possessing multi-scale fermentation capabilities capable of producing both high volume and low volume fermentation based products.

Continuous investment in R&D

As of 31 March 2026, Symbiotec had three dedicated R&D centers and R&D activities were organised across organic chemistry, biotechnology and complex injectables platforms. R&D expenditure was ₹29.70 crore, or 3.42% of revenue, in FY26, ₹31.14 crore, or 4.14% of revenue, in FY25 and ₹20.51 crore, or 2.86% of revenue, in FY24.

Strong financial metrics

Return on Capital Employed (ROCE) adjusted for capital expenditure not yet commissioned was at 30.43%, 27.71% and 24.59% in FY26, FY25 and FY24 respectively. Net cash flow from operating activities were ₹174.59 crore in FY26, ₹47.26 crore in FY25 and ₹187.50 crore in FY24.

About Symbiotec Pharmalab Limited

Symbiotec Pharmalab is a science based pharmaceutical and biotechnology company, driven by research and development with over 30 years of industry experience. It was incorporated in 2002 after founding as a lab-scale steroidal-hormone API manufacturer in 1995.

Over the years, the company has evolved into an industrial-scale, backward-integrated manufacturing platform with capabilities across organic chemistry, biotechnology and complex injectables. As of March 31, 2026, Symbiotec had over 200 customers in more than 40 countries including leading generic and specialty pharmaceutical companies in the United States, Europe and Asia.

The company has global volume market shares at 38.2% and 23.8% for corticosteroid APIs and steroidal-hormone APIs respectively as of FY26. It is also the only Indian and global company with a presence across the top 10 corticosteroid and steroidal-hormone APIs. The company operates as a contract development and manufacturing organization (CDMO), providing services to specialty pharmaceutical and nutraceutical companies globally.

Symbiotec operates through three complementary business verticals: API products, CDMO services and complex injectables. In FY26, API products accounted for 96.07% of revenue from operations at ₹835.01 crore, while complex injectables contributed 3.80% at ₹33.05 crore and CDMO services contributed 0.13% at ₹1.09 crore. The company has a product portfolio of over 60 corticosteroid and steroidal-hormone APIs supplied globally, including Hydrocortisones, Betamethasones, Methylprednisolones, Progesterones, Estrogens and Testosterones. These products are used across critical care setups and chronic therapeutic areas.

As of March 31, 2026, Symbiotec operated two industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres (KL). The Rau Facility in Indore houses sterile and non-sterile corticosteroid API manufacturing blocks, with a maximum capacity of 92 MT as of March 31, 2026. The Pithampur Facility comprises dedicated and isolated blocks for steroidal-hormone and corticosteroid API manufacturing, with a maximum fermentation capacity of 300 KL and maximum chemical synthesis capacity of 492.67 MT.

The company has also commissioned two additional manufacturing facilities at Ujjain and Mhow, Madhya Pradesh, taking its aggregate maximum chemical synthesis capacity to 584.67 MT, maximum fermentation capacity to 700 KL and complex injectables capacity to 20 million vials per annum.

As of March 31, 2026, Symbiotec had over 50 domestic customers and over 150 export customers, serving key generic and specialty pharmaceutical companies across North America, Europe and Asia. The company added 101 new distinct customers in FY26. In FY26, 67.04% of revenue from operations was generated from international markets, while 32.96% was generated from domestic markets, including indirect exports to regulated markets. Europe contributed 29.11% of revenue while the United States contributed 13.12% and the rest of the World contributed 24.81% in FY26. As of March 31, 2026, Symbiotec’s R&D staff comprised 156 scientists and engineers. Of these, 117 had master’s degrees and 10 possessed PhDs. The company has spent 3.42%, 4.14% and 2.86% of revenue from operations on R&D in FY26, FY25 and FY24 respectively.

The continued global prevalence of inflammatory and autoimmune diseases such as rheumatoid arthritis, asthma, chronic obstructive pulmonary disease and inflammatory bowel disease continue to drive demand for corticosteroid active pharmaceutical ingredients (APIs). Research shows that up to 10% of people in industrialised nations suffer from at least one autoimmune disease. The steroid hormones API market is also boosted by rising demand for reproductive health, metabolic disorder and hormone replacement therapies.

The specialty ingredients market, which includes nutraceuticals, functional foods, industrial enzymes, and agricultural biologicals, was valued at US$ 749.0 billion in 2025, and is projected to expand at a CAGR of 6.7% over the period from 2025 to 2030. The biologics pharmaceutical market is estimated to be worth US$82.3 billion in 2025 and is projected to grow at a CAGR of 11.0% creating opportunities in the company's biotechnology-led efforts.

Symbiotec has invested over ₹798.61 crore in the last three fiscal years to build additional capacities and capabilities in API and complex injectables manufacturing. Capital expenditure was ₹237.31 crore in FY26, ₹392.90 crore in FY25 and ₹176.66 crore in FY24. A slow shift in fermentation API production away from China is being driven by growing geopolitical concerns, supply chain vulnerabilities and tightening environmental regulations. Against this backdrop, Symbiotec has observed an increase in requests for proposals from global pharmaceutical companies. The company expects this trend to support further expansion of its market share, particularly in the United States and European Union markets, supported by its regulatory track record.

Now, Symbiotec Pharmalab is launching its initial public offering (IPO), which consists of a fresh issue of ₹150 crore and an offer for sale of ₹1,607 crore only. The total issue size of the IPO is ₹1,757 crore. Its shares will be listed on the NSE and BSE.

How to apply for Symbiotec Pharmalab IPO?

If you are interested in this investment opportunity but unsure how to apply for Symbiotec Pharmalab IPO, here are the steps that you need to follow.

When the public issue opens for subscription, one can follow this step-by-step guide on how to apply for Symbiotec Pharmalab IPO on Upstox:

Log in to your Upstox account, using your six-digit PIN
After logging in, click on ‘Discover’
On the ‘Discover’ tab, you will find the ‘Invest in IPO’ section
Under the Invest in IPO section, look for the ‘Symbiotec Pharmalab IPO’ tab and click on it
Now fill in all the required information, like ‘bid price’ and ‘lot size’
Confirm and click on ‘Apply’
Accept the mandate on your UPI app

IPO Analysis

IPO REVIEW

Symbiotec Pharmalab IPO | Analysis Video

Symbiotec Pharmalab IPO

Should you apply?

View Video

Symbiotec Pharmalab IPO Subscription Status

Date	QIB	NII	Retail	Total
24-Aug-26	0.35 times (X)	2.52 times (X)	0.67 times (X)	0.72 times (X)
25-Aug-26	0.36X	7.21X	1.45X	1.57X
26-Aug-26	0.42X	36.43X	5.08X	6.2X
27-Aug-26	142.47X	219.87X	12.76X	82.94X

Latest News on Symbiotec Pharmalab IPO

Symbiotec Pharmalab IPO is a fresh issuance of equity shares valued at ₹150 crore and an offer for sale (OFS) component of shares totalling ₹1,607 crore.

2 min read

Symbiotec Pharmalab IPO will be a mix of a fresh issue of equity shares worth ₹150 crore and an offer for sale (OFS) of ₹2,030 crore by a promoter and existing investors, according to the preliminary papers.

2 min read

The ₹1,757 crore Symbiotec Pharmalab IPO comprises a fresh issue of shares worth up to ₹150 crore and an offer for sale (OFS) component amounting to ₹1,607 crore by promoter Satwani Holdings LLP and investors Rosewood Investments and India Business Excellence Fund-III.

3 min read

The ₹1,757 crore Symbiotec Pharmalab IPO is a combination of a fresh issue of equity shares worth up to ₹150 crore and an offer for sale (OFS) amounting to ₹1,607 crore.

2 min read

Symbiotec Pharmalab IPO sought to raise ₹1,757 crore via fresh issuance of equity shares totalling ₹150 crore and an offer for sale (OFS) of ₹1,607 crore.

3 min read

Symbiotec Pharmalab IPO aimed to raise ₹1,757 crore through fresh issuance of equity shares valued at ₹150 crore and an offer for sale (OFS) component of ₹1,607 crore.

2 min read

Frequently asked questions

How to invest in the Symbiotec Pharmalab IPO ?

Investors can apply for the Symbiotec Pharmalab IPO through their Demat account via the stock exchange or through their broker.

What is the issue size of Symbiotec Pharmalab IPO ?

The issue size of the Symbiotec Pharmalab IPO is 1757 Cr.

What is 'pre-apply' for Symbiotec Pharmalab IPO ?

Pre-applying for an IPO allows you to submit your application before the official subscription period begins.

Which exchanges will Symbiotec Pharmalab IPO shares list on?

The IPO shares will typically list on major stock exchanges such as the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), as specified in the IPO prospectus.